Edwards Lifesciences Corporation (NYSE:EW) Shares Bought by Bank Hapoalim BM

Bank Hapoalim BM boosted its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) by 7.5% during the first quarter, HoldingsChannel.com reports. The institutional investor owned 30,460 shares of the medical research company’s stock after purchasing an additional 2,120 shares during the quarter. Bank Hapoalim BM’s holdings in Edwards Lifesciences were worth $2,208,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Crowley Wealth Management Inc. acquired a new position in Edwards Lifesciences during the fourth quarter worth $26,000. Vega Investment Solutions acquired a new position in Edwards Lifesciences during the fourth quarter worth $27,000. Millstone Evans Group LLC acquired a new position in Edwards Lifesciences during the fourth quarter worth $29,000. Global X Japan Co. Ltd. boosted its stake in Edwards Lifesciences by 116.1% during the first quarter. Global X Japan Co. Ltd. now owns 402 shares of the medical research company’s stock worth $29,000 after buying an additional 216 shares during the last quarter. Finally, Tradewinds Capital Management LLC boosted its stake in Edwards Lifesciences by 102.5% during the first quarter. Tradewinds Capital Management LLC now owns 405 shares of the medical research company’s stock worth $29,000 after buying an additional 205 shares during the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Insiders Place Their Bets

In other news, CFO Scott B. Ullem sold 11,250 shares of the stock in a transaction dated Friday, May 9th. The stock was sold at an average price of $74.40, for a total value of $837,000.00. Following the transaction, the chief financial officer owned 41,098 shares in the company, valued at approximately $3,057,691.20. This represents a 21.49% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Daveen Chopra sold 1,500 shares of the stock in a transaction dated Thursday, May 22nd. The shares were sold at an average price of $75.08, for a total value of $112,620.00. Following the completion of the transaction, the vice president owned 33,496 shares in the company, valued at approximately $2,514,879.68. The trade was a 4.29% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 40,348 shares of company stock worth $2,977,683. 0.34% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of research firms have weighed in on EW. Wall Street Zen lowered Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Friday, May 16th. Citigroup reaffirmed a “buy” rating and issued a $95.00 price target (up previously from $84.00) on shares of Edwards Lifesciences in a research note on Thursday, May 22nd. Truist Financial decreased their price target on Edwards Lifesciences from $78.00 to $75.00 and set a “hold” rating on the stock in a research note on Friday, April 11th. Robert W. Baird upped their price target on Edwards Lifesciences from $72.00 to $75.00 and gave the company a “neutral” rating in a research note on Thursday, April 24th. Finally, Dbs Bank raised Edwards Lifesciences to a “hold” rating in a research note on Monday, June 2nd. One investment analyst has rated the stock with a sell rating, fourteen have issued a hold rating and eleven have issued a buy rating to the company’s stock. According to data from MarketBeat, Edwards Lifesciences presently has a consensus rating of “Hold” and a consensus price target of $80.20.

Edwards Lifesciences Price Performance

Shares of NYSE EW opened at $76.64 on Tuesday. The stock’s 50-day moving average is $76.14 and its two-hundred day moving average is $73.29. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.45 and a quick ratio of 3.66. Edwards Lifesciences Corporation has a 1-year low of $58.93 and a 1-year high of $95.25. The company has a market cap of $44.96 billion, a price-to-earnings ratio of 10.95, a price-to-earnings-growth ratio of 3.86 and a beta of 1.11.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share for the quarter, topping the consensus estimate of $0.60 by $0.04. Edwards Lifesciences had a return on equity of 16.62% and a net margin of 75.48%. The company had revenue of $1.41 billion for the quarter, compared to the consensus estimate of $1.40 billion. During the same quarter in the prior year, the business earned $0.66 EPS. Edwards Lifesciences’s revenue was up 6.2% on a year-over-year basis. Analysts forecast that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.